Xie Yafeng, Zhou Yiming, Yang Jing, Xu Man
Institution of Pathogenic Biology, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, China.
Department of Clinical Laboratory, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China.
ACS Omega. 2025 Apr 16;10(16):16853-16862. doi: 10.1021/acsomega.5c00495. eCollection 2025 Apr 29.
Syphilis is a significant multistage sexually transmitted infection caused by the bacterium . The pathogenesis of this pathogen remains inadequately understood, impeding the progress of syphilis vaccine development. Our prior study has demonstrated the potential of the Tp0663 protein as a viable candidate for a vaccine against . In the present study, we sought to explore the protective response of dual immunization using two different antigenic entities (i.e., flagellin FlaB3 and lipoprotein Tp0663) against in a murine model. Our investigation revealed that FlaB3 + Tp0663 can elicit robust humoral and cellular immune responses. In addition, the FlaB3 + Tp0663 vaccine demonstrated a notable reduction in the Treponemal burden within various anatomical sites of infected mice, including the blood, brain, liver, lymph nodes, spleen, and testicles. It is worth noting that the FlaB3 + Tp0663 vaccine suppressed the dissemination of in C57BL/6 mice. The findings demonstrate that flagellin FlaB3 may augment the immunoprotection of Tp0663. This represents a valuable practical perspective and offers insights into developing a syphilis vaccine.
Front Immunol. 2021
Diagn Microbiol Infect Dis. 2016-2
ACS Infect Dis. 2025-3-14
Vaccine. 2013-10-14
Lancet. 2023-7-22
Front Immunol. 2023
Curr Opin Virol. 2023-6
Front Immunol. 2021
N Engl J Med. 2020-2-27
Mucosal Immunol. 2018-11-28